查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858007

万古霉素市场按剂型、给药途径、适应症、最终用户和分销管道划分－全球预测，2025-2032年

Vancomycin Market by Dosage Form, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，万古霉素市场规模将成长 11.0576 亿美元，复合年增长率为 5.12%。

关键市场统计数据
基准年 2024 7.4153亿美元
预计年份：2025年 7.7923亿美元
预测年份 2032 11.0576亿美元
复合年增长率 (%) 5.12%

全面分析影响万古霉素在医院、诊所和输液环境中使用的临床相关性、供应动态和营运压力。

万古霉素仍然是医院环境中的基石抗生素，广泛用于治疗严重的革兰氏阳性感染疾病，以及在抗药性限制其他药物使用的情况下进行治疗。经过数十年的临床应用，万古霉素已从最后的治疗方法发展成为经验性治疗和标靶治疗方案的重要组成部分，特别适用于治疗抗药性金黄色葡萄球菌感染和某些严重的梭状菌感染。近年来，住院治疗路径的改变、对抗生素管理的重视以及製剂和给药方式的创新，正在显着改变临床医生和医疗系统应用这种治疗方法的方式。

在此临床背景下，供应链动态变化和日益严格的监管审查迫使製造商和供应链相关人员重新评估其采购、製造地和分销策略。同时，艰难梭菌感染治疗监测、剂量优化和口服製剂的进展正在改变处方模式，并对药房和输液服务提出了新的营运要求。这些临床和营运因素与更广泛的政策和贸易环境相互作用，影响筹资策略、价格谈判和医院的处方决策。

本执行摘要总结了影响价值链各相关人员的最显着趋势，重点阐述了变革性转变、关税主导的压力、细分市场特有的考量以及区域性动态。该分析旨在为临床负责人、采购主管、法规事务专业人员和商业团队提供清晰、可操作的观点，从而将临床需求与市场现实相结合。

重要的临床、生产和政策转变汇聚在一起，重新定义了整个医疗保健系统中万古霉素的部署、监测和供应策略。

万古霉素领域正经历一系列变革性转变，这些转变是由临床、技术和政策趋势的融合所驱动，并重新定义了相关人员的优先事项。在临床方面，人们越来越重视精准给药和治疗药物监测，以优化疗效并降低毒性；同时，为了支持个人化治疗，方案和实验室整合的趋势也在加速发展。

从技术角度来看，针对肠道标靶治疗设计的口服製剂的改进正在增强门诊艰难梭菌感染疾病的管理，减少某些人群的住院时间，并改变住院患者对肠外产品的需求模式；同时，冻干工艺和无菌生产的创新正在使注射产品能够更稳定、更长期地储存，增强医院药房的库存管理并减少浪费。

在政策层面，更严格的抗生素管理指南和对抗生素研发奖励日益严格的审查，正促使支付者和医疗系统更密切地评估临床路径和成本效益。供应链韧性已成为一项策略重点，製造商正致力于製造外包的多元化，并采用关键原材料的冗余采购。这些转变共同推动相关人员采取整合策略，将卓越的临床疗效、稳健的供应和透明的成本相结合。

美国2025年关税调整将如何改变必需抗生素和无菌注射剂的采购、库存和生产决策

美国2025年关税政策导致某些药品和医药中间体的进口成本上升，对生产、分销和采购环节造成直接和间接压力。无菌注射剂和冷冻干燥药品中使用的原料和辅料通常来自全球各地，关税上涨将增加到岸投入成本，迫使生产商和经销商调整筹资策略和成本分摊方式。

因此，供应链相关人员正在评估近岸外包方案，选择替代供应商，并协商长期合约以稳定单价波动。分销相关人员正在重新评估其库存策略，重点关注关键无菌产品的安全库存，以降低发货时间风险。医疗系统内的采购团队正在寻求价格保护、灵活的合约条款以及提高成本驱动因素的透明度，以支持预算编制週期。

关税也促使人们讨论垂直整合和对本地製造业的投资。一些製造商正在探索在免税地区扩大产能，或参与公私合作，以确保国内基本抗生素的可靠生产。这些措施将受到监管审查，因为本地生产必须符合无菌和品质标准，这会在策略韧性和即时供应需求之间造成时间上的紧张关係。

临床医生可能会感受到采购限制和临床需求交织的后续影响，例如处方采购惯例、替代方案以及更严格的药品管理标准。积极调整采购方式、实现供应商多元化并完善临床指南的相关人员，更有可能在应对关税带来的成本压力的同时，维持医疗服务的连续性和疗效。

基于可操作的细分洞察，将剂型、给药途径、适应症、最终用户和分销管道与营运和临床重点联繫起来。

细分市场分析揭示了不同剂型、给药途径、适应症、最终用户和分销管道的临床和商业考量，这些因素都会影响产品需求和营运重点。按剂型划分，本文检视了冻干粉注射、口服製剂和肠外溶液，重点分析了它们在储存方法、復溶流程和门诊适用性方面的差异。冷冻干燥粉製剂通常需要復溶和严格的低温运输管理，这决定了药房和输液中心的流程；而口服製剂则可用于肠道标靶治疗的门诊治疗。注射液的床边配製时间较短，但可能有保存期限限制。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 万古霉素抗药性肠球菌的出现推动了对下一代糖肽类抗生素的需求。
  • 加强治疗药物监测在重症加护环境中的应用，以优化药物剂量
  • 门诊病人中口服万古霉素用于治疗艰难梭菌感染疾病的仿单标示外用药增加
  • 加速研发长效万古霉素类似物，以减少给药频率并提高病患依从性
  • 万古霉素：价格压力不断增加，促使人们更加关注具有成本效益的学名药供应链策略
  • 扩大对基于奈米颗粒的递送系统的研究，以增强万古霉素的靶向抗生素治疗
  • 对万古霉素杂质监管力道的加强促使生产製程创新。
  • 生技公司与学术机构加强合作，以发现新的万古霉素衍生物

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 万古霉素市场按剂型划分

  • 注射用冻干粉
  • 口服
  • 注射液

9. 万古霉素市场依给药途径划分

  • 静脉注射
  • 口服

10. 万古霉素市场依适应症划分

  • 艰难梭菌感染疾病
  • 抗药性金黄色葡萄球菌治疗
  • 手术预防

第十一章 万古霉素市场（依最终用户划分）

  • 门诊手术中心
    • 多专科中心
    • 单一专科中心
  • 诊所
    • 门诊部
    • 专科诊所
  • 医院
    • 社区医院
    • 三级医院

12. 万古霉素市场按分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

13. 万古霉素市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 万古霉素市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国万古霉素市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Viatris Inc.
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals PLC
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma Limited
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Ltd.
Product Code: MRR-C002B1C99629

The Vancomycin Market is projected to grow by USD 1,105.76 million at a CAGR of 5.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 741.53 million
Estimated Year [2025] USD 779.23 million
Forecast Year [2032] USD 1,105.76 million
CAGR (%) 5.12%

Comprehensive context on clinical relevance, supply dynamics, and operational pressures shaping vancomycin use across hospitals, clinics, and infusion settings

Vancomycin remains a cornerstone antibiotic in hospital settings, widely deployed to treat serious gram-positive infections and to manage cases where resistance limits the utility of other agents. Over decades of clinical use, vancomycin has evolved from a last-resort therapy to a key element of empiric and targeted treatment protocols, particularly in the management of methicillin-resistant Staphylococcus aureus and certain severe clostridial infections. Recent shifts in inpatient care pathways, an emphasis on antimicrobial stewardship, and innovations in formulation and administration are reshaping how clinicians and health systems deploy this therapy.

Against this clinical backdrop, supply chain dynamics and regulatory scrutiny have intensified, prompting manufacturers and supply-chain stakeholders to re-evaluate sourcing, manufacturing footprints, and distribution strategies. Concurrently, advances in therapeutic monitoring, dose optimization, and oral formulations for Clostridioides difficile management have altered prescribing patterns and created new operational requirements for pharmacies and infusion services. These clinical and operational forces interplay with broader policy and trade environments, influencing procurement strategy, pricing negotiations, and hospital formulary decisions.

This executive summary synthesizes the most salient developments affecting stakeholders across the value chain, highlighting transformative shifts, tariff-driven pressures, segmentation-specific considerations, and regionally distinct dynamics. The analysis is designed to equip clinical leaders, procurement executives, regulatory affairs professionals, and commercial teams with clear, actionable perspectives that bridge clinical imperatives and market realities.

Critical clinical, manufacturing, and policy shifts converging to redefine vancomycin deployment, monitoring, and supply strategies across healthcare systems

The landscape for vancomycin is undergoing a set of transformative shifts driven by converging clinical, technological, and policy trends that are redefining stakeholder priorities. Clinically, there is a stronger emphasis on precision dosing supported by therapeutic drug monitoring to mitigate toxicity while optimizing efficacy, which has accelerated adoption of protocols and laboratory integrations that support individualized therapy.

Technologically, improvements in oral formulations designed for gut-targeted therapy have enhanced outpatient management of Clostridioides difficile infections, reducing hospital lengths of stay for select cohorts and changing demand patterns for inpatient parenteral formulations. Meanwhile, innovations in lyophilization processes and sterile manufacturing are enabling more stable injection products with extended shelf life, which enhances inventory management and reduces wastage for hospital pharmacies.

On the policy front, tighter antimicrobial stewardship guidelines and growing scrutiny of antibiotic pipeline incentives are prompting payers and health systems to more closely evaluate clinical pathways and cost-effectiveness. Supply-chain resilience has become a strategic priority, with manufacturers diversifying contract manufacturing partners and adopting redundant sourcing for critical raw materials. Together, these shifts are pushing stakeholders toward integrated strategies that combine clinical excellence with supply robustness and cost transparency.

How the 2025 tariff shifts in the United States are altering sourcing, inventory, and manufacturing decisions for essential antibiotics and sterile injectables

The 2025 tariff environment in the United States introduced elevated import costs for certain pharmaceuticals and pharmaceutical intermediates, creating direct and indirect pressures across manufacturing, distribution, and procurement functions. Raw materials and excipients used in sterile injectable and lyophilized products are often sourced globally, and increased tariffs can raise landed input costs, necessitating adjustments in sourcing strategies or absorption of costs by manufacturers and distributors.

As a result, supply-chain actors have been evaluating nearshoring options, qualifying alternate suppliers, and negotiating longer-term contracts to stabilize unit-cost volatility. Distribution players have reassessed inventory strategies, placing greater emphasis on safety stock for critical sterile products to mitigate shipment timing risks. Procurement teams within health systems are responding by seeking pricing protections, flexible contract terms, and enhanced transparency into cost drivers to support budgeting cycles.

Tariffs also accelerate conversations about vertical integration and localized manufacturing investments. Some manufacturers are exploring capacity expansions in tariff-exempt jurisdictions or engaging in public-private collaborations to secure reliable domestic production for essential antibiotics. Regulatory oversight accompanies these moves, as local production must meet sterility and quality standards, creating a timeline tension between strategic resilience and immediate supply needs.

Clinicians may feel the downstream effects through formulary reviews, substitution protocols, and tighter stewardship criteria when procurement constraints intersect with clinical demand. Stakeholders who proactively align procurement practices, supplier diversification, and clinical guidelines will be better positioned to navigate tariff-induced cost pressures while maintaining continuity of care and therapeutic effectiveness.

Actionable segmentation-driven insights linking dosage forms, routes, indications, end users, and distribution channels to operational and clinical priorities

Segmentation analysis illuminates distinct clinical and commercial considerations across dosage forms, routes of administration, indications, end users, and distribution channels, each influencing product demand and operational priorities. Based on Dosage Form, market is studied across Lyophilized Powder For Injection, Oral Formulation, and Solution For Injection, which highlights differences in storage, reconstitution workflows, and outpatient applicability. Lyophilized powders often require reconstitution and strict cold-chain management, creating workflow demands in pharmacy and infusion centers, whereas oral formulations enable ambulatory treatment pathways for gut-targeted indications. Solution for injection products reduce bedside preparation time but may impose shorter shelf-life constraints.

Based on Route Of Administration, market is studied across Intravenous and Oral, with intravenous formulations concentrated in acute care settings where rapid systemic exposure is required, and oral routes predominantly used for localized gastrointestinal therapy and outpatient regimens. Therapeutic monitoring and dosing complexity differ substantially by route, influencing laboratory ties and nursing workflows. Based on Indication, market is studied across Clostridioides Difficile Infections, Methicillin Resistant Staphylococcus Aureus Treatment, and Surgical Prophylaxis, which underscores varying clinical protocols, stewardship imperatives, and perioperative stocking practices. C. difficile therapy drives demand for gut-active oral formulations, MRSA treatment centers on systemic parenteral delivery and monitoring, and surgical prophylaxis requires predictable supply within operating suite logistics.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. The Ambulatory Surgical Centers is further studied across Multi Specialty Centers and Single Specialty Centers. The Clinics is further studied across Outpatient Clinics and Specialty Clinics. The Hospitals is further studied across Community Hospitals and Tertiary Care Hospitals, reflecting how institutional scale, procedural mix, and pharmacy capabilities shape product preference and inventory strategies. Finally, based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, which identifies divergent procurement practices, dispensing regulations, and patient access considerations. Together, these segmentation lenses create a nuanced picture that supports targeted clinical protocols, procurement decision rules, and commercialization tactics tailored to each stakeholder group.

Regionally differentiated dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive vancomycin availability, procurement, and clinical adoption

Regional dynamics shape availability, regulatory pathways, and clinical utilization patterns for vancomycin in differentiated ways across the globe. In the Americas, healthcare systems exhibit a mix of centralized purchasing in public institutions and competitive private procurement, which influences contracting cycles and supplier negotiations. North American clinical practice has increasingly integrated therapeutic drug monitoring and stewardship protocols that affect inpatient utilization of parenteral formulations, while Latin American markets often face challenges related to supply continuity and procurement transparency, prompting reliance on regional distributors and alternate sourcing strategies.

In Europe, Middle East & Africa, variations in reimbursement policies, procurement mechanisms, and regulatory harmonization create a complex mosaic. Several European markets emphasize national guidelines and tender-based procurement for hospital drugs, which drives supplier consolidation and standardized product specifications. In parts of the Middle East and Africa, infrastructure limitations and logistics hurdles can affect cold-chain reliability for injectable products, leading stakeholders to prioritize stability and shelf-life in supplier selection. Cross-border regulatory alignment efforts and regional manufacturing investments are influencing medium-term supply strategies.

The Asia-Pacific region contains a wide spectrum of markets, from advanced economies with stringent regulatory controls and robust domestic manufacturing to emerging markets where rapid hospital expansion and evolving stewardship frameworks are reshaping demand. Many Asia-Pacific manufacturers play significant roles in global active pharmaceutical ingredient supply, so regional trade policy and manufacturing capacity shifts have outsized implications for global availability. Across all regions, alignment between clinicians, procurement teams, and suppliers-supported by clear data on product handling, monitoring needs, and clinical indications-remains foundational to ensuring reliable patient access.

Strategic company behaviors and supply-chain partnerships that drive resilience, quality differentiation, and long-term institutional relationships in vancomycin supply

The competitive and collaborative dynamics among manufacturers, contract manufacturers, and distributors are central to resilience and innovation in the vancomycin supply chain. Established producers of sterile injectables invest in capacity and quality systems to meet hospital-grade standards, while smaller specialty manufacturers focus on niche formulations or supply to regional markets. Contract manufacturing organizations play a pivotal role in scaling lyophilization capacity and in enabling redundancy when primary sites face disruptions. Distributors and wholesalers that integrate cold-chain logistics and real-time inventory visibility have become strategic partners for health systems aiming to reduce stockouts and manage expiries.

Strategic alliances between manufacturers and hospital systems, such as long-term supply agreements and joint investment in manufacturing resilience, are increasingly common. These collaborations help align production planning with clinical demand and create incentives for process improvements that reduce variability. Pharmaceutical developers are also exploring incremental formulation enhancements that improve handling or extend shelf life, which can improve operational efficiency in pharmacies and infusion centers.

From a regulatory and quality perspective, companies that demonstrate robust compliance, transparent quality data, and rapid responsiveness to adverse events earn preferential consideration in institutional procurement. Firms that proactively engage with clinicians, stewardship committees, and procurement leaders to support training on dosing and monitoring can differentiate themselves beyond price, building long-term relationships grounded in clinical outcomes and operational reliability.

Practical and strategic recommendations for procurement, manufacturing, and clinical leaders to enhance resilience and clinical value in vancomycin supply

Industry leaders should adopt a dual approach that combines immediate operational resilience with medium-term strategic investments to secure clinical continuity and competitive advantage. Near-term actions include diversifying supplier portfolios for critical raw materials and finished products, establishing contractual protections such as price floors and volume commitments, and enhancing inventory management practices with real-time visibility and tiered safety stock aligned to clinical priority levels. Procurement teams should partner closely with antimicrobial stewardship and clinical pharmacy to align stocking policies with evidence-based protocols that reduce unnecessary usage while preserving access for high-priority indications.

Medium-term recommendations emphasize manufacturing resilience and value-based engagement. Investing in regional manufacturing capacity or partnering with contract manufacturers in low-tariff jurisdictions can reduce exposure to trade shocks and logistical delays. Concurrently, companies should invest in formulation improvements that simplify administration and extend shelf life, thereby reducing wastage and operational burdens on hospital pharmacies. Commercial teams should position offerings around total cost of care, emphasizing clinical support services such as dosing guidance, therapeutic drug monitoring facilitation, and education for surgical and ambulatory teams.

Finally, all stakeholders should prioritize data transparency and collaborative contingency planning. Sharing anonymized usage and inventory data across supplier networks and health systems can enable predictive replenishment and targeted interventions during shortages. By combining operational rigor, clinical partnership, and strategic investment, industry leaders can maintain patient access and differentiate through reliability and value.

Methodological overview describing source integration, segmentation logic, and analytical approach used to derive practical vancomycin insights without numeric forecasting

This analysis synthesizes evidence from peer-reviewed clinical literature, regulatory agency guidance, manufacturing quality standards, and documented trade policy developments to create an integrated perspective on vancomycin dynamics. Clinical sections draw on recent guideline updates, antimicrobial stewardship frameworks, and pharmacokinetic-pharmacodynamic literature to describe dosing, monitoring, and indication-specific considerations. Supply-chain and tariff implications are informed by reported changes in trade policy, publicly available customs frameworks, and observable industry responses such as supplier diversification and production adjustments.

The segmentation approach integrates product characteristics, routes of administration, indications, end-user capabilities, and distribution channels to map operational requirements to stakeholder needs. Regionally focused insights are derived from comparative policy analysis, regulatory paradigms, and documented logistics constraints that affect cold-chain and sterile product distribution. Company-level observations incorporate public statements on capacity investments, quality certifications, and strategic partnerships, coupled with industry-standard best practices for sterile manufacturing and distribution.

While the methodology prioritizes triangulation across multiple credible sources and expert practitioner perspectives, the synthesis intentionally avoids speculative numerical projections. Instead, the emphasis is on actionable interpretations of observed trends, validated clinical practices, and operational levers that can be employed by decision-makers to manage risk and capitalize on emerging opportunities.

Concise synthesis emphasizing coordinated clinical, procurement, and manufacturing actions required to preserve access and therapeutic value for vancomycin

In conclusion, vancomycin continues to occupy an essential role in the therapeutic arsenal against serious gram-positive infections, but its near-term trajectory is being reshaped by clinical best practices, formulation innovations, and evolving trade and manufacturing dynamics. Clinicians and health systems face the twin imperatives of optimizing clinical outcomes through precision dosing and stewardship while ensuring continuous supply in the face of tariff-induced cost pressures and global sourcing variability. Hospitals, clinics, and ambulatory surgical centers must therefore synchronize clinical protocols with procurement strategies and supplier engagement to maintain both access and value.

Manufacturers and supply-chain partners that invest in quality, redundancy, and formulation enhancements will be better positioned to meet institutional expectations and to negotiate long-term agreements that balance cost and reliability. Strategic coordination across the value chain-supported by transparent data sharing, aligned contracting, and contingency planning-will be the decisive factor in mitigating disruption and ensuring patient-centered care. By acting on the recommendations outlined in this summary, stakeholders can translate insight into operational resilience and sustained clinical effectiveness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of vancomycin-resistant enterococci driving demand for next-generation glycopeptides
  • 5.2. Increasing integration of therapeutic drug monitoring to optimize vancomycin dosing in critical care settings
  • 5.3. Rising off-label use of oral vancomycin formulations for treatment of Clostridioides difficile infections in outpatient settings
  • 5.4. Accelerated development of long-acting vancomycin analogs for reduced dosing frequency and improved patient compliance
  • 5.5. Growing focus on cost-effective generic vancomycin supply chain strategies amid pricing pressures
  • 5.6. Expanding research into nanoparticle-based vancomycin delivery systems enhancing targeted antimicrobial therapy
  • 5.7. Strengthening regulatory scrutiny on vancomycin impurities prompting manufacturing process innovations
  • 5.8. Increasing collaborations between biotech firms and academic institutions for novel vancomycin derivative discovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vancomycin Market, by Dosage Form

  • 8.1. Lyophilized Powder For Injection
  • 8.2. Oral Formulation
  • 8.3. Solution For Injection

9. Vancomycin Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Vancomycin Market, by Indication

  • 10.1. Clostridioides Difficile Infections
  • 10.2. Methicillin Resistant Staphylococcus Aureus Treatment
  • 10.3. Surgical Prophylaxis

11. Vancomycin Market, by End User

  • 11.1. Ambulatory Surgical Centers
    • 11.1.1. Multi Specialty Centers
    • 11.1.2. Single Specialty Centers
  • 11.2. Clinics
    • 11.2.1. Outpatient Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Hospitals
    • 11.3.1. Community Hospitals
    • 11.3.2. Tertiary Care Hospitals

12. Vancomycin Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Vancomycin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vancomycin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vancomycin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
    • 16.3.3. Novartis AG
    • 16.3.4. Viatris Inc.
    • 16.3.5. Fresenius Kabi AG
    • 16.3.6. Hikma Pharmaceuticals PLC
    • 16.3.7. Dr. Reddy's Laboratories Ltd.
    • 16.3.8. Aurobindo Pharma Limited
    • 16.3.9. Sun Pharmaceutical Industries Ltd.
    • 16.3.10. Glenmark Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VANCOMYCIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VANCOMYCIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VANCOMYCIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS VANCOMYCIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS VANCOMYCIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. GCC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. GCC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. GCC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. GCC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. GCC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 314. GCC VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 315. GCC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. GCC VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. GCC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 318. GCC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 319. GCC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 320. GCC VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 321. GCC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 322. GCC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 323. GCC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. GCC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS VANCOMYCIN MARKET SIZE, BY AMBULATORY SUR